SpringWorks Therapeutics Inc Ordinary Shares SWTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SWTX is a good fit for your portfolio.
News
-
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
-
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
-
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
-
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
-
SpringWorks Therapeutics to Present at Upcoming Investor Conferences
-
Thinking about trading options or stock in Estee Lauder, Apple, Arista Networks, Walt Disney, or SpringWorks Therapeutics?
-
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Trading Information
- Previous Close Price
- $44.00
- Day Range
- $43.03–44.93
- 52-Week Range
- $18.00–53.92
- Bid/Ask
- $34.30 / $68.97
- Market Cap
- $3.21 Bil
- Volume/Avg
- 504,700 / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 509.90
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 305
- Website
- https://www.springworkstx.com
Comparables
Valuation
Metric
|
SWTX
|
VRDN
|
CELC
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 5.16 | 2.99 | 3.15 |
Price/Sales | 509.90 | 1,857.18 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
SWTX
VRDN
CELC
Financial Strength
Metric
|
SWTX
|
VRDN
|
CELC
|
---|---|---|---|
Quick Ratio | 6.21 | 17.93 | 12.78 |
Current Ratio | 6.41 | 18.26 | 13.43 |
Interest Coverage | — | −137.76 | −12.43 |
Quick Ratio
SWTX
VRDN
CELC
Profitability
Metric
|
SWTX
|
VRDN
|
CELC
|
---|---|---|---|
Return on Assets (Normalized) | −39.61% | −42.76% | −35.57% |
Return on Equity (Normalized) | −45.43% | −82.42% | −49.08% |
Return on Invested Capital (Normalized) | −49.28% | −50.70% | −39.21% |
Return on Assets
SWTX
VRDN
CELC
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qlsbnyqgqw | Bwgkp | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lcjbfqxx | Cwghc | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cvdnghpn | Prygtc | $99.5 Bil | |
MRNA
| Moderna Inc | Hnvmwgwcb | Rrq | $38.8 Bil | |
ARGX
| argenx SE ADR | Fznryrlb | Wdfx | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Rsbhyrwh | Nxx | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dlbhznfzf | Dwdnt | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Khyqmlmq | Swlwx | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dlwgrlbnf | Wskzvxj | $12.5 Bil | |
INCY
| Incyte Corp | Pbqbfbd | Bxspqh | $11.6 Bil |